Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04084717
Recruitment Status : Recruiting
First Posted : September 10, 2019
Last Update Posted : April 1, 2021
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.

Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.


Condition or disease Intervention/treatment Phase
Non-squamous Non-small-cell Lung Cancer Stage IV Non-small Cell Lung Cancer ROS1 Gene Rearrangement MET Activating Mutation MET Amplification Drug: Crizotinib Phase 2

Detailed Description:

The study consists of a screening period, study drug period, end of study drug visit and follow-up period.

During the screening period, participants will be asked to have tests and procedures done to make sure that they are eligible to continue in the study. Screening may take several visits. Participants found to be eligible to continue in the study, will then enter the study drug period where they will take the study drug and have tests and procedures done about once a week for safety and for research purposes.

Participants who stop the study drug completely for any reason, will be asked to return to the clinic for an end of study drug visit about 28 days after their last dose of study drug to have tests and procedures done for safety and for research purposes. Participants that are experiencing any side effects during this time, will be closely followed by their study Doctor until the side effects have resolved or stabilized.

Participants who discontinue study drug for any reason other than disease progression, will be asked to have radiological imaging every 8 weeks to follow up on the status of their disease, until disease progression or the start a new treatment for their cancer.

After their final visit, the study nurse will call participants approximately every 3 months to check on the status of their health.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Participants will be assigned to one of the following:

Cohort 1 - ROS1 rearrangement Cohort 2 - MET-activating mutation (exon 14) Cohort 3 - MET-amplification

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)
Actual Study Start Date : December 3, 2019
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Crizotinib

Arm Intervention/treatment
Experimental: ROS1 Rearrangement
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
Drug: Crizotinib

Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.

Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.

Other Name: XALKORI

Experimental: MET-activating Mutation (exon 14)
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
Drug: Crizotinib

Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.

Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.

Other Name: XALKORI

Experimental: MET-amplification
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
Drug: Crizotinib

Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.

Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.

Other Name: XALKORI




Primary Outcome Measures :
  1. Response Rate [ Time Frame: 5 years ]
    Via RECIST 1.1

  2. Progression-free survival [ Time Frame: 5 years ]
    Via RECIST 1.1

  3. Average Time-to-treatment Failure [ Time Frame: 5 years ]
    Time from randomization to treatment discontinuation for any reason

  4. Edmonton Symptom Assessment Scale (ESAS) Score [ Time Frame: 5 years ]
    Patient related symptom improvement evaluated by ESAS

  5. EQ5D-3L Questionnaire Score [ Time Frame: 5 years ]
    Patient preference/health related utility evaluated by EQ5D-3L Questionnaire

  6. Overall survival [ Time Frame: 2 years ]
    Number of days from the date of randomization to the date of death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable
  • 18 years of age or older.
  • Measurable disease as per RECIST v1.1.
  • Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment
  • Life expectancy >12 weeks.
  • Have the ability to understand and the willingness to sign a written informed consent document
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • No contraindication to Crizotinib therapy
  • Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  • No pregnant
  • Agree to use methods (as agreed upon by the study doctor and participant) before the study and for at least 120 days after the last dose of study drug to prevent pregnancy

Exclusion Criteria:

  • Symptomatic untreated brain metastases.
  • Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks prior to the proposed first dose of study treatment.
  • Adverse events attributed to prior anti-cancer therapy > Grade 1 if clinically relevant.
  • Receiving medications or substances known to be strong inhibitors or inducers of CYP3A4.
  • Any known intolerance to agents structurally similar to crizotinib.
  • Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula (QTcF) ≥ 500 msec.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04084717


Contacts
Layout table for location contacts
Contact: Natasha Leighl, M.D. 416-946-4645 natasha.leighl@uhn.ca

Locations
Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 1Z5
Contact: Natasha Leighl    416-946-4645    natasha.leighl@uhn.ca   
Principal Investigator: Natasha Leighil, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Natasha Leighl, M.D. Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT04084717    
Other Study ID Numbers: 18-5607
CROME / WI235747 ( Other Identifier: Princess Margaret Cancer Centre )
First Posted: September 10, 2019    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Crizotinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action